MYCB1 utilizes its proprietary ALETTA® Real-World Data management platform to enhance patient adherence and outcomes for individuals undergoing chronic therapy. The company aims to improve patient quality of life by providing data-driven, ultra-personalized healthcare lifestyle solutions.
Funding
$45M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients undergoing chronic therapy often struggle with adherence to treatment plans, leading to suboptimal outcomes and reduced quality of life. Current healthcare approaches may not adequately address individual patient needs and lifestyle factors that impact adherence.
Solution
MYCB1 leverages its ALETTA® Real-World Data management platform to provide data-driven, personalized healthcare lifestyle solutions aimed at enhancing patient adherence and improving outcomes for individuals undergoing chronic therapy. The platform collects and analyzes real-world data to identify individual patient needs and challenges related to their treatment. By understanding these factors, MYCB1 delivers tailored interventions and support to help patients better manage their conditions and adhere to their prescribed therapies. This approach aims to improve patient quality of life by addressing the specific barriers they face in maintaining their treatment regimens.
Target Audience
The primary target audience consists of individuals undergoing chronic therapy and healthcare providers seeking to improve patient adherence and outcomes.
Features
- ALETTA® Real-World Data management platform for collecting and analyzing patient data
- Personalized healthcare lifestyle solutions tailored to individual patient needs
- Data-driven insights to identify factors impacting patient adherence
- Targeted interventions and support to improve treatment adherence